Washington University School of Medicine: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 21 Squamous Cell Carcinoma of Head and Neck studies with Washington University School of Medicine as lead sponsor. 5 are open to participants now and 9 have results posted.

Phase 1 6Phase 2 17No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Indocyanine Green With Near Infrared Imaging for Intraoperative Visualization of Head and Neck Squamous Cell CarcinomaRecruitingNCT07825597
• CCR2 PET Imaging Head and Neck Squamous Cell CarcinomaRecruitingNCT07659678Phase 2
• Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/2
• 5-Fluorouracil Response and Optimization STudy (The FROST Trial)RecruitingNCT07419464Phase 2
• Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell CarcinomaRecruitingNCT04852328Phase 2
• Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based ChemotherapyTerminatedNCT03655444Phase 1/2Results posted
• Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03650764Phase 1/2Results posted
• Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03389477Phase 2Results posted
• Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)CompletedNCT02573493Phase 2Results posted
• Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard TherapiesCompletedNCT02369458Phase 2Results posted
• Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT02296684Phase 2Results posted
• PD 0332991 and Cetuximab in Patients With Incurable SCCHNCompletedNCT02101034Phase 1/2Results posted
• Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck CancerCompletedNCT00736944Phase 2Results posted
• Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck CancerCompletedNCT00671437Phase 2Results posted
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT05980000Phase 2
• Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 InhibitorActive, not recruitingNCT04831320Phase 2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
• Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT02270814Phase 2
• Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT01716416Phase 1
• Effectiveness in Head and Neck Cancer Detection Using Positron Emission Tomography (PET) Insert DeviceWithdrawnNCT01133262